Subscribe To
PROF / Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
PROF News
By Seeking Alpha
November 4, 2023
Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menaw more_horizontal
By GlobeNewsWire
October 19, 2023
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med more_horizontal
By GlobeNewsWire
September 19, 2023
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage me more_horizontal
By Zacks Investment Research
September 19, 2023
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions more_horizontal
By Seeking Alpha
August 9, 2023
Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat more_horizontal
By Zacks Investment Research
August 9, 2023
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to los more_horizontal
By GlobeNewsWire
August 2, 2023
Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow
TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med more_horizontal
By Seeking Alpha
June 22, 2023
Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%
Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid grow more_horizontal